DEA Places Brexanolone Into Schedule IV
The Drug Enforcement Administration placed the neurosteroid brexanolone into Schedule IV of the Controlled Substances Act, it said. The final rule confirms an interim regulation issued in June that subjected brexanolone to new registration, labeling, recordkeeping, and import and export requirements.
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
(Federal Register 01/24/20)